Interview
with Neil Love, MD from Breast Cancer Update for Medical Oncologists,
Program 3 2000
Play
Audio Below:
They
took advantage of their enormous data set to go back and look at
immunohistochemical analysis on a bunch of tumors where they already
had classic receptor binding assays, and my short take of that trial
– and they had clinical follow-up on all these women –
was that the immunohistochemistry was just as good and, in some
instances, maybe a little bit better. They tried to do a cut-off
analysis to figure out what is positive by immunohistochemistry,
and I remember Gary Clark getting up and saying that in their hands
basically even as few as 1% of your cells staining positive, in
this particular analysis, suggested that there was some tamoxifen
benefit. So, I’ve taken that into my practice as saying that
unless it says ER negative PR negative, I pretty routinely think
about tamoxifen. I must say I don’t think about it as hard
in that situation as I do if people have very positive receptors.
But if it says anything remotely positive, it crosses my mind.
Youth
and hormone receptors in breast cancer: good or bad news first? Stockler, M. and Beith, J. (Reprint available from: Stockler
M Univ Sydney, Natl Hlth & Med Res Council, Clin Trials Ctr,
Dept Med Sydney NSW 2006 Australia). Lancet. 355(9218): 1839-1840,
2000 May 27. No abstract
